Lumexa Imaging (NASDAQ:LMRI) Posts Quarterly Earnings Results

Lumexa Imaging (NASDAQ:LMRI) issued its quarterly earnings data on Tuesday. The company reported $0.18 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $252.54 million for the quarter.

Here are the key takeaways from Lumexa Imaging’s conference call:

• Q1 results were in line with expectations despite seasonal and weather-related disruption, and management said volumes recovered through March with momentum improving into Q2.
• Advanced imaging remains the main growth engine, with advanced modality volumes up 7% year over year, PET up 23.1%, and MRI up 8.2% in the quarter.
• The company is expanding through de novos, acquisitions, and JV partnerships, having opened two de novos and completed two acquisitions this year while staying on track to open 8-10 de novos annually.
• Management reaffirmed full-year guidance for revenue of $1.045 billion-$1.097 billion and adjusted EBITDA of $234 million-$242 million, while expecting a heavier earnings contribution in the back half of the year.
• The call highlighted technology and efficiency initiatives, including FastScan rollout to about two-thirds of MRI machines by end-2026 and broader use of AI and virtual tools to improve throughput and operations.

Lumexa Imaging Stock Performance

Shares of NASDAQ:LMRI traded up $0.34 on Tuesday, reaching $10.50. 479,356 shares of the company traded hands, compared to its average volume of 798,541. Lumexa Imaging has a fifty-two week low of $7.23 and a fifty-two week high of $19.45. The firm has a 50 day simple moving average of $10.90.

Institutional Trading of Lumexa Imaging

Several large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. acquired a new stake in Lumexa Imaging during the 1st quarter valued at $63,000. Bank of New York Mellon Corp acquired a new stake in Lumexa Imaging during the 1st quarter valued at $479,000. Emerald Mutual Fund Advisers Trust raised its stake in Lumexa Imaging by 11.0% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 653,342 shares of the company’s stock valued at $5,619,000 after purchasing an additional 64,677 shares during the period. Principal Financial Group Inc. raised its stake in Lumexa Imaging by 1.2% during the 1st quarter. Principal Financial Group Inc. now owns 664,136 shares of the company’s stock valued at $5,712,000 after purchasing an additional 7,875 shares during the period. Finally, Hunter Associates Investment Management LLC acquired a new stake in Lumexa Imaging during the 1st quarter valued at $1,231,000.

Wall Street Analyst Weigh In

LMRI has been the subject of a number of research reports. Barclays decreased their price target on Lumexa Imaging from $23.00 to $15.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Raymond James Financial raised Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 price objective on the stock in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Strong Buy” and a consensus price target of $19.00.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).